Rhythm Pharmaceuticals, Inc. Forecast, price target & analysts
Rhythm Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Rhythm Pharmaceuticals, Inc. Classifications & Recommendation:
Rhythm Pharmaceuticals, Inc. Price Target
| Target Price | $129.54 |
| Price | $112.27 |
| Potential |
15.38%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2026 .
The average Rhythm Pharmaceuticals, Inc. target price is $129.54.
This is
15.38%
register free of charge
$148.05
31.87%
register free of charge
$111.10
1.04%
register free of charge
|
|
| A rating was issued by 21 analysts: 19 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2026 of
15.38%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 130.13 | 191.73 |
| 68.06% | 47.34% | |
| EBITDA Margin | -202.83% | -101.37% |
| 13.99% | 50.02% | |
| Net Margin | -203.31% | -113.56% |
| 14.76% | 44.14% |
17 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
17 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.34 | -3.27 |
| 35.63% | 24.65% | |
| P/E | negative | |
| EV/Sales | 37.48 |
17 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
Current Rhythm Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 22 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Dec 17 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Citizens |
Locked
➜
Locked
|
Locked | Dec 12 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Dec 11 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 25 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 22 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Dec 17 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Citizens:
Locked
➜
Locked
|
Dec 12 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Dec 11 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 25 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
